Soleno Therapeutics, Inc.
SLNO•NASDAQ•Healthcare•Biotechnology

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOAnish Bhatnagar
Founded1999
IPO DateNovember 13, 2014
Employees92
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitesoleno.life
Phone650 213 8444
Address
100 Marine Parkway, Suite 400 Redwood City, California 94065 United States

Corporate Identifiers

CIK0001484565
CUSIP834203200
ISINUS8342033094
EIN77-0523891
SIC2834

Leadership Team & Key Executives

Dr. Anish Bhatnagar M.D.
Chairman, President, Chief Executive Officer and Chief Operating Officer
James H. MacKaness
Chief Financial Officer and Compliance Officer
Patricia C. Hirano M.P.H.
Senior Vice President of Regulatory Affairs
Meredith Manning M.B.A.
Chief Commercial Officer
Jesse Schumaker
General Counsel
Lauren Budesheim
Senior Vice President of People
Kristen Yen M.S.
Senior Vice President of Global Clinical Operations and Patient Advocacy
Dr. Neil M. Cowen M.B.A., Ph.D.
Senior Vice President of New Product Planning
Dr. Michael Huang M.D.
Senior Vice President of Clinical Development
Dr. Mitchell Nagao M.B.A., Pharm.D.
Senior Vice President of Medical Affairs